Brittany G Craiglow1, Lynn M Boyden2, Ronghua Hu1, Marie Virtanen3, John Su4, Gabriela Rodriguez5, Catherine McCarthy6, Paula Luna7, Margarita Larralde7, Stephen Humphrey8, Kristen E Holland8, Marcia Hogeling9, Benjamin Hidalgo-Matlock5, Bruno Ferrari7, Esteban Fernandez-Faith10, Beth Drolet8, Kelly M Cordoro11, Anne M Bowcock12, Richard J Antaya13, Kurt Ashack14, Richard J Ashack15, Richard P Lifton2, Leonard M Milstone1, Amy S Paller16, Keith A Choate17. 1. Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut. 2. Department of Genetics, Yale University School of Medicine, New Haven, Connecticut. 3. Department of Dermatology, Uppsala University Hospital, Uppsala, Sweden. 4. Department of Dermatology, Monash University, Eastern Health, Melbourne, Australia; Department of Pediatrics, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia. 5. Department of Dermatology, University of Costa Rica, San Jose, Costa Rica. 6. Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri. 7. Department of Pediatric Dermatology, Ramos Mejía Hospital, Buenos Aires, Argentina. 8. Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin. 9. Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles, California. 10. Department of Pediatrics and Dermatology, The Ohio State University Medical Center, Columbus, Ohio; Department of Pediatrics and Dermatology, Nationwide Children's Hospital, Columbus, Ohio. 11. Department of Dermatology, University of California, San Francisco, California; Department of Pediatrics, University of California, San Francisco, California. 12. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Genetics and Genome Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. 13. Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut; Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut. 14. Department of Dermatology, University of Illinois at Chicago College of Medicine, Chicago, Illinois. 15. Dermatology Associates of West Michigan, Grand Rapids, Michigan. 16. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 17. Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut; Department of Genetics, Yale University School of Medicine, New Haven, Connecticut; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. Electronic address: keith.choate@yale.edu.
Abstract
BACKGROUND: Heterozygous mutations in caspase recruitment domain family member 14 gene (CARD14) have been shown to be associated with psoriasis and familial pityriasis rubra pilaris (PRP). Many subjects with CARD14 mutations display features of both disorders, which can result in diagnostic uncertainty. In addition, these eruptions are often recalcitrant to conventional psoriasis therapies such as methotrexate, oral retinoids, and tumor necrosis factor-α inhibitors. OBJECTIVE: We sought to describe the clinical characteristics, family history, and response to therapy in subjects with papulosquamous eruptions due to mutations in CARD14. METHODS: Subjects were referred for genetic testing as part of a registry of subjects with inherited disorders of keratinization. DNA was isolated from blood or saliva, and multiplex targeted sequencing or whole exome sequencing was performed. Clinical histories of subjects with CARD14 mutations were reviewed. RESULTS: We identified 15 kindreds with CARD14-associated papulosquamous eruption (CAPE). Characteristic features of CAPE include early age of onset; prominent involvement of the cheeks, chin, and ears; family history of psoriasis or PRP; minimal response to conventional topical and systemic psoriasis therapies; and improvement with ustekinumab. LIMITATIONS: Relatively small sample size. CONCLUSIONS: Many subjects with CARD14 mutations display characteristics of both psoriasis and PRP. We propose the term CARD14-associated papulosquamous eruption to describe this spectrum of disease. Subjects with clinical features suggestive of CAPE should undergo CARD14 sequencing and may benefit from treatment with ustekinumab.
BACKGROUND: Heterozygous mutations in caspase recruitment domain family member 14 gene (CARD14) have been shown to be associated with psoriasis and familial pityriasis rubra pilaris (PRP). Many subjects with CARD14 mutations display features of both disorders, which can result in diagnostic uncertainty. In addition, these eruptions are often recalcitrant to conventional psoriasis therapies such as methotrexate, oral retinoids, and tumor necrosis factor-α inhibitors. OBJECTIVE: We sought to describe the clinical characteristics, family history, and response to therapy in subjects with papulosquamous eruptions due to mutations in CARD14. METHODS: Subjects were referred for genetic testing as part of a registry of subjects with inherited disorders of keratinization. DNA was isolated from blood or saliva, and multiplex targeted sequencing or whole exome sequencing was performed. Clinical histories of subjects with CARD14 mutations were reviewed. RESULTS: We identified 15 kindreds with CARD14-associated papulosquamous eruption (CAPE). Characteristic features of CAPE include early age of onset; prominent involvement of the cheeks, chin, and ears; family history of psoriasis or PRP; minimal response to conventional topical and systemic psoriasis therapies; and improvement with ustekinumab. LIMITATIONS: Relatively small sample size. CONCLUSIONS: Many subjects with CARD14 mutations display characteristics of both psoriasis and PRP. We propose the term CARD14-associated papulosquamous eruption to describe this spectrum of disease. Subjects with clinical features suggestive of CAPE should undergo CARD14 sequencing and may benefit from treatment with ustekinumab.
Authors: Mark Lebwohl; Newman Yeilding; Philippe Szapary; Yuhua Wang; Shu Li; Yaowei Zhu; Kristian Reich; Richard G Langley; Kim A Papp Journal: J Am Acad Dermatol Date: 2010-10 Impact factor: 11.527
Authors: Catherine T Jordan; Li Cao; Elisha D O Roberson; Shenghui Duan; Cynthia A Helms; Rajan P Nair; Kristina Callis Duffin; Philip E Stuart; David Goldgar; Genki Hayashi; Emily H Olfson; Bing-Jian Feng; Clive R Pullinger; John P Kane; Carol A Wise; Raphaela Goldbach-Mansky; Michelle A Lowes; Lynette Peddle; Vinod Chandran; Wilson Liao; Proton Rahman; Gerald G Krueger; Dafna Gladman; James T Elder; Alan Menter; Anne M Bowcock Journal: Am J Hum Genet Date: 2012-04-19 Impact factor: 11.025
Authors: Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich Journal: Lancet Date: 2008-05-17 Impact factor: 79.321
Authors: Cindy P Frare; Alli J Blumstein; Amy S Paller; Lia Pieretti; Keith A Choate; Anne M Bowcock; Margarita Larralde Journal: Pediatr Dermatol Date: 2021-08-26 Impact factor: 1.997
Authors: Dylan Haynes; Jennifer L Strunck; Christina A Topham; Alex G Ortega-Loayza; Gail Kent; Pamela B Cassidy; Ronghua Hu; Keith Choate; Zhiping Wang; Yuangang Liu; Teri M Greiling Journal: JAMA Dermatol Date: 2020-06-01 Impact factor: 10.282
Authors: Sarah K Baxter; Tom Walsh; Silvia Casadei; Mary M Eckert; Eric J Allenspach; David Hagin; Gesmar Segundo; Ming K Lee; Suleyman Gulsuner; Brian H Shirts; Kathleen E Sullivan; Michael D Keller; Troy R Torgerson; Mary-Claire King Journal: J Allergy Clin Immunol Date: 2021-04-20 Impact factor: 10.793
Authors: Joan Manils; Louise V Webb; Ashleigh Howes; Julia Janzen; Stefan Boeing; Anne M Bowcock; Steven C Ley Journal: Elife Date: 2020-06-29 Impact factor: 8.713